Compare IIIN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIN | LYEL |
|---|---|---|
| Founded | 1953 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.9M | 401.8M |
| IPO Year | 1994 | 2021 |
| Metric | IIIN | LYEL |
|---|---|---|
| Price | $27.46 | $17.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | ★ 156.7K | 57.7K |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | ★ 112.12 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $647,706,000.00 | $36,000.00 |
| Revenue This Year | $14.20 | N/A |
| Revenue Next Year | $6.82 | $8,712.13 |
| P/E Ratio | $42.42 | ★ N/A |
| Revenue Growth | ★ 22.39 | N/A |
| 52 Week Low | $24.35 | $7.78 |
| 52 Week High | $41.64 | $45.00 |
| Indicator | IIIN | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 38.32 |
| Support Level | $24.42 | $15.74 |
| Resistance Level | $27.53 | $19.02 |
| Average True Range (ATR) | 0.85 | 1.12 |
| MACD | 0.40 | 0.03 |
| Stochastic Oscillator | 82.10 | 41.50 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.